Key Highlights
- Oppenheimer expects the new proposal to face legal challenges.
- The rule revives a 2023 audit rule.
- A federal judge in Texas vacated that rule in September 2025.
- The case was brought by Humana.
A rule with a legal history
The Centers for Medicare & Medicaid Services (CMS) released a proposed rule on Monday, November 16, that has knocked health insurer stocks hard for two straight sessions. Its full name is "Comprehensive Regulations to Uncover Suspicious Healthcare," shortened to CRUSH. It would let CMS take error findings from Medicare Advantage risk adjustment data validation (RADV) audits of a sample of records and apply them to an entire contract, with the lookback reaching back to payment year 2018.
The legal history matters. The proposal revives a 2023 RADV rule that a federal judge in Texas vacated in September 2025, in a case brought by Humana (NYSE:HUM). With that background, Oppenheimer has said it expects the new proposal to face legal challenges. The firm has also said it thinks plans would price the cost into their bids. Oppenheimer has not been reported as forecasting how any challenge would end, and no court has ruled on the new proposal.
What Oppenheimer said about the numbers
One analyst pointed to the scale of the recovery estimate. "The substantially larger collection estimate reflects broader auditing," he said. He added that CMS "could choose to make adjustments in the final rule."
CMS estimates the rule would bring in about $9 billion per payment year and about $90 billion over 10 years. CMS's estimate is $90.2 billion recovered from 2027 through 2036. The rule is not final, and its terms could still change before CMS adopts it.
How the market reacted
The selling was concentrated and steep. Humana was the worst performer in the S&P 500 on Wednesday, November 18, and UnitedHealth Group (NYSE:UNH) was the worst stock in the Dow Jones Industrial Average, which fell 561.25 points to 50,198.17. Elevance Health (NYSE:ELV), Centene (NYSE:CNC) and CVS Health (NYSE:CVS) also slid, and Cigna (NYSE:CI) and Molina Healthcare (NYSE:MOH) lost ground too. It was the second straight day of declines for the group.
Humana's exposure is the largest among the big names. Medicare Advantage made up $99.4 billion of its $129.7 billion in 2025 revenue. Its shares sank further than its large peers' on Wednesday.
CMS's framing
CMS describes the proposal as an anti-fraud effort. CMS Administrator Dr. Mehmet Oz framed it as a way to "crush fraud, waste, and abuse." That is the agency's description of its aim. Insurers can respond through the formal comment process, which is open until January 19, 2027.
Medicare Advantage is the program through which private insurers run Medicare benefits for seniors who choose it, with the government paying plans based partly on how sick their members are recorded to be. RADV audits check whether submitted diagnoses are backed up by medical records.
A Rule With a Legal History Faces a New Test
The first marker is January 19, 2027, the deadline for public comments. After that, CMS would review the feedback and could issue a final rule, which Oppenheimer has said could include adjustments. Investors will be watching whether any company or trade group files a lawsuit once a final rule is published, given the 2023 rule's fate in the Texas court. UnitedHealth is also expected to give its 2027 outlook before the end of the year, which could offer the first detailed management view on how the proposal might affect planning.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...